| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | 18% | +65% | $3,078,992 | +$1,349,571 | 2,462,012 | +78% | Phillip Frost, M.D. | 28 Oct 2025 |
As of 30 Sep 2025, 21 institutional investors reported holding 664,983 shares of Cocrystal Pharma, Inc. - Common Stock, par value $0.001 per share (COCP). This represents 4.8% of the company’s total 13,831,528 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 3,303 | $3,233 | +$3,151 | $0.98 | 2 |
| 2025 Q3 | 664,983 | $831,250 | -$40,107 | $1.25 | 21 |
| 2025 Q2 | 686,516 | $1,022,928 | -$87,903 | $1.49 | 21 |
| 2025 Q1 | 748,773 | $1,064,069 | +$47,077 | $1.42 | 23 |
| 2024 Q4 | 711,406 | $1,437,067 | -$15,959 | $2.02 | 24 |
| 2024 Q3 | 719,274 | $1,265,944 | +$79,057 | $1.76 | 19 |
| 2024 Q2 | 674,355 | $1,571,278 | -$90,505 | $2.33 | 13 |
| 2024 Q1 | 721,322 | $1,013,555 | +$53,971 | $1.40 | 14 |
| 2023 Q4 | 683,341 | $1,173,672 | -$61,072 | $1.72 | 16 |
| 2023 Q3 | 704,225 | $1,316,878 | +$61,521 | $1.87 | 15 |
| 2023 Q2 | 666,895 | $1,594,259 | -$144,985 | $2.39 | 19 |
| 2023 Q1 | 738,638 | $1,468,069 | -$651,564 | $1.99 | 19 |
| 2022 Q4 | 1,065,912 | $2,076,645 | +$2,076,609 | $1.95 | 18 |